In May, the German group that pioneered the treatment in rheumatic disease reported on a troubling syndrome they dubbed ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center recently opened the Roswell Park GMP Engineering & Cell Manufacturing Facility, a $98 million cell and gene therapy hub aimed at growing ...

One of the most striking breakthroughs of Belarusian medicine in the field of oncology is CAR‑T‑cell therapy. 85 people have already ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

PHILADELPHIA – A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

Patients relapsing within three months post-CAR T-cell therapy have lower response rates to BsAb therapy compared to those relapsing after six months. Elevated LDH levels and higher international ...